Ute Schaeper
YOU?
Author Swipe
View article: Maternal Tmprss6 is required for hepcidin suppression and fetal health
Maternal Tmprss6 is required for hepcidin suppression and fetal health Open
The antenatal role of the hepcidin-regulating protease Tmprss6 has never been elucidated as knockout dams are infertile. Utilising an in vivo knockdown approach, we confirm Tmprsss6 is critical for hepcidin suppression in pregnancy, and Tm…
View article: Modulatory effects of CNNM4 on protein-l-isoaspartyl-O-methyltransferase repair function during alcohol-induced hepatic damage
Modulatory effects of CNNM4 on protein-l-isoaspartyl-O-methyltransferase repair function during alcohol-induced hepatic damage Open
Background and Aims: Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality worldwide, with limited treatment options beyond abstinence and liver transplantation. Chronic alcohol consumption has been linked to…
View article: Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model
Myelodysplastic Syndromes Benefit from Iron-Restricted Bone Marrow Transplant in Preclinical Mouse Model Open
Background: Hematopoietic stem cell transplantation (HSCT) remains the only fully curative therapy for diseases such as b-thalassemia, sickle cell disease, MDS and AML and represents a relevant procedure for gene therapy .Tissue iron overl…
View article: S286: TARGETING CONDITIONING-ELICITED NON-TRANSFERRIN-BOUND IRON BY TMPRSS6 SILENCING IMPROVES BONE MARROW TRANSPLANT OUTCOME
S286: TARGETING CONDITIONING-ELICITED NON-TRANSFERRIN-BOUND IRON BY TMPRSS6 SILENCING IMPROVES BONE MARROW TRANSPLANT OUTCOME Open
Background: Hematopoietic stem cell transplantation (HSCT) remains the only fully curative therapy for diseases such as b-thalassemia, sickle cell disease, MDS and AML and a relevant procedure for gene therapy. Tissue iron overload and, re…
View article: SLN124, a GalNAc conjugated 19‐mer siRNA targeting <i>tmprss6</i>, reduces plasma iron and increases hepcidin levels of healthy volunteers
SLN124, a GalNAc conjugated 19‐mer siRNA targeting <i>tmprss6</i>, reduces plasma iron and increases hepcidin levels of healthy volunteers Open
SLN124, an N‐acetylgalactosamine conjugated 19‐mer short interfering RNA, is being developed to treat iron‐loading anemias (including beta‐thalassemia and myelodysplastic syndromes) and myeloproliferative neoplasms (polycythemia vera). Thr…
View article: Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
Purpose: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hem…
View article: Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 485K
View article: Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 477K
View article: Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 2 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 477K
View article: Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 174K
View article: Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 82K
View article: Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 3 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 82K
View article: Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 4 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 174K
View article: Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Data from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
Purpose: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hem…
View article: Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Supplementary Figure 1 from Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models Open
PDF file - 485K
View article: Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 3 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 5 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the vasculature of mice. Here we report preclinical data for Atu027, a siRNA-lipoplex directed against protein kinase N3 …
View article: Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Data from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the vasculature of mice. Here we report preclinical data for Atu027, a siRNA-lipoplex directed against protein kinase N3 …
View article: Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 2 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 6 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Figure 4 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
View article: Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Open
Supplementary Table 1 from Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression